A carregar...
Publicação
Cytokine profile of inflammatory bowel diseases patients
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 698.87 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that comprises Crohn´s disease (CD) and Ulcerative colitis (UC). IBD etiopathogenesis is partly understood and includes both genetic and environmental factors, inducing an abnormal immune response. However, risk factors associated with these pathologies point to a combination of environmental and genetic components. The IBD pathophysiology is understood as a cytokine-induced inflammatory response. Several data referred that there is a significant association of IBD and oral conditions, namely tooth decay and periodontal disease. Medications such as anti-inflammatories, corticosteroids and biological therapies are the treatment of choice for these chronic conditions, depending on the etiology. Thus, understanding immune dysregulation, exploring novel biomarkers, and advancing therapeutic strategies contribute to better managing IBD and improving patient outcome. The identification, quantification and/or validation of biomarkers is primarily performed in tissue, blood and fecal samples but only few studies have been done with saliva, which reflects the same type of biomarkers, allowing noninvasive sample collection. This work aims to study the inflammatory profile of IBD patients, exploring new salivary biomarkers for monitoring diseases status, identifying high-risk patients allowing target interventions.